PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12196129-6	2002	In humans, lovastatin, an HMG-CoA reductase inhibitor, has been shown to reduce A beta levels in blood of patients by up to 40%.	Lovastatin	11-21	amyloid beta precursor protein	Homo sapiens	80-86	
26096465-6	2015	We demonstrated that lovastatin can differentially affect the expression of APP and Abeta production in vivo and in vitro.	Lovastatin	21-31	amyloid beta precursor protein	Homo sapiens	76-89	
17907956-7	2007	This is indicated by a reported ability of micromolar concentrations of lovastatin and simvastatin to strongly stimulate brain vascular endothelial cells to make this Abeta ejector.	Lovastatin	72-82	amyloid beta precursor protein	Homo sapiens	167-172	
16675062-0	2006	Influence of cholesterol and lovastatin on alpha-form of secreted amyloid precursor protein and expression of alpha7 nicotinic receptor on astrocytes.	Lovastatin	29-39	amyloid beta precursor protein	Homo sapiens	66-91	
16675062-1	2006	The influence of cholesterol and the lovastatin (cholesterol-lowering drug) on secretion of alpha-secretase cleavage product of amyloid precursor protein (APP) and expression of nicotinic acetylcholine receptors (nAChRs) was investigated in human HTB-15 astrocytes.	Lovastatin	37-47	amyloid beta precursor protein	Homo sapiens	128-153	
29341888-0	2018	Protection against the Neurotoxic Effects of beta-Amyloid Peptide on Cultured Neuronal Cells by Lovastatin Involves Elevated Expression of alpha7 Nicotinic Acetylcholine Receptors and Activating Phosphorylation of Protein Kinases.	Lovastatin	96-106	amyloid beta precursor protein	Homo sapiens	45-65	
29341888-2	2018	To examine the pleiotropic cholesterol-independent effects of statins in connection with the treatment of Alzheimer disease, we probed the influence of lovastatin on the metabolism of amyloid precursor protein (APP), expression of nicotinic acetylcholine receptors (nAChRs), and activity of mitogen-activated protein kinase (MAPK) in primary cultured neurons and SH-SY5Y cells overexpressing human APP670/671.	Lovastatin	152-162	amyloid beta precursor protein	Homo sapiens	184-209	
29341888-3	2018	Lovastatin attenuated the neurotoxic effects of beta-amyloid peptide (Abeta) and affected the metabolism of APP, reducing levels of Abeta1 to Abeta42 and beta-site amyloid precursor protein-cleaving enzyme 1; enhancing those of alphaAPP, disintegrin metalloproteinase domain-containing protein 10, and beta-site amyloid precursor protein-cleaving enzyme 2; and up-regulating expression of alpha7 nAChR and stimulating phosphorylation of extracellular signal-regulated kinase (ERK)1/2.	Lovastatin	0-10	amyloid beta precursor protein	Homo sapiens	48-68	
17234346-0	2007	Lovastatin protects human neurons against Abeta-induced toxicity and causes activation of beta-catenin-TCF/LEF signaling.	Lovastatin	0-10	amyloid beta precursor protein	Homo sapiens	42-47	
17234346-5	2007	Lovastatin has been shown to decrease the production of Abeta and to promote neuronal survival.	Lovastatin	0-10	amyloid beta precursor protein	Homo sapiens	56-61	
17234346-8	2007	Here, we report that lovastatin prevented Abeta-induced apoptosis in human SK-NSH cells.	Lovastatin	21-31	amyloid beta precursor protein	Homo sapiens	42-47	
17234346-12	2007	Our results suggest that lovastatin protects neuronal cells from Abeta-induced apoptosis and causes reduction in GSK-3beta activity, resulting in activation of Wnt signaling.	Lovastatin	25-35	amyloid beta precursor protein	Homo sapiens	65-70	
11900994-10	2002	Our results suggest a mechanism by which hypercholesterolemia may increase risk for AD and indicate that lovastatin reduces Abeta formation and may thereby be effective in delaying the onset and/or slowing the progression of AD.	Lovastatin	105-115	amyloid beta precursor protein	Homo sapiens	124-129	
11900994-0	2002	Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients.	Lovastatin	66-76	amyloid beta precursor protein	Homo sapiens	117-137	
10501560-1	1999	Addition of the beta-hydroxy-beta-methylglutaryl-CoA (HmG-CoA) reductase inhibitor lovastatin to human HEK cells transfected with the amyloid precursor protein (APP) reduces intracellular cholesterol/protein ratios by 50%, and markedly inhibits beta-secretase cleavage of newly-synthesized APP.	Lovastatin	83-93	amyloid beta precursor protein	Homo sapiens	134-159	
11466161-0	2001	Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide.	Lovastatin	34-44	amyloid beta precursor protein	Homo sapiens	85-105	
11466161-2	2001	Studies in vitro have shown that inhibiting cholesterol metabolism with lovastatin, or its active metabolite lovastatin acid, lowers A beta production.	Lovastatin	72-82	amyloid beta precursor protein	Homo sapiens	133-139	
9600988-4	1998	By reducing the cellular cholesterol level of living hippocampal neurons by 70% with lovastatin and methyl-beta-cyclodextrin, we show that the formation of Abeta is completely inhibited while the generation of APPsec is unperturbed.	Lovastatin	85-95	amyloid beta precursor protein	Homo sapiens	156-161